摘要
Abstract
Objective To evaluate the clinical value of next-generation sequencing(NGS)in neonatal disease screening,particularly its advantages when combined with tandem mass spectrometry(MS/MS).Methods A prospective study was conducted involving blood samples from 1 999 neonates born at the Shenzhen Guangming District People's Hospital,between May and August 2021.All samples were initially screened using MS/MS and fluorescence immunoassay,followed by NGS to detect high-frequency variation sites in 135 related pathogenic genes.Suspected positive variants were validated using Sanger sequencing or multiplex ligation-dependent probe amplification in family studies.Results No confirmed positive cases were found in the MS/MS analysis of the 1 999 neonates.Genetic screening identified 58 positive cases(2.90%),732 carriers of pathogenic genes(36.62%),and 1 209 negative cases(60.48%).One case of neonatal intrahepatic cholestasis was diagnosed(0.05%,1/1 999).Fluorescence immunoassay identified 39 cases of glucose-6-phosphate dehydrogenase(G6PD)deficiency(1.95%,39/1 999),while genetic screening identified 43 cases of G6PD deficiency(2.15%,43/1 999).The fluorescence immunoassay also detected 6 cases of hyperthyrotropinemia(0.30%,6/1 999),all of whom carried DUOX2 gene variants.The top ten pathogenic gene carrier rates were G6PD(12.8%),DUOX2(8.7%),HBB(8.2%),ATP7B(6.6%),GJB2(5.7%),SLC26A4(5.6%),PAH(5.6%),ACADSB(4.6%),SLC25A13(4.2%),and SLC22A5(4.1%).Conclusions NGS can serve as an effective complement to MS/MS,significantly improving the detection rate of inherited metabolic disorders in neonates.When combined with family validation,it enables precise diagnosis,particularly demonstrating complementary advantages in screening for monogenic diseases such as G6PD deficiency.关键词
基因筛查/串联质谱/新生儿筛查/遗传代谢病/新生儿Key words
Genetic screening/Tandem mass spectrometry/Neonatal screening/Inherited metabolic disorder/Neonate
